Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on Kodiak Sciences. The associated price target remains the same with $40.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors surrounding Kodiak Sciences’ recent developments and promising data. The extended follow-up results from the Phase 1b APEX study for KSI-101, a bispecific agent targeting IL-6 and VEGF, have shown consistent improvements in visual acuity and anatomical outcomes without additional safety concerns. This reinforces confidence in the ongoing Phase 3 PEAK and PINNACLE studies, which aim to further validate these findings.
Moreover, KSI-101’s performance appears superior when compared to Roche’s competing IL-6 monospecific asset, vamikibart, particularly in terms of efficacy and safety. Given the potential setbacks for Roche, Kodiak Sciences’ KSI-101 could emerge as the first approved IVT injection targeting IL-6, positioning it as a best-in-class treatment. The anticipation of pivotal data in the coming years further supports the optimistic outlook for Kodiak Sciences, justifying the Buy rating.
According to TipRanks, Dolezal is ranked #1345 out of 10072 analysts.
In another report released on October 26, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.